EP4055176A4 - Vaccins anti-gucy2c et vaccination - Google Patents

Vaccins anti-gucy2c et vaccination Download PDF

Info

Publication number
EP4055176A4
EP4055176A4 EP20960974.2A EP20960974A EP4055176A4 EP 4055176 A4 EP4055176 A4 EP 4055176A4 EP 20960974 A EP20960974 A EP 20960974A EP 4055176 A4 EP4055176 A4 EP 4055176A4
Authority
EP
European Patent Office
Prior art keywords
gucy2c
vaccination
vaccines
gucy2c vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20960974.2A
Other languages
German (de)
English (en)
Other versions
EP4055176A1 (fr
Inventor
Adam E. Snook
Scott A Waldman
Trevor R. BAYBUTT
John C. FLICKINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP4055176A1 publication Critical patent/EP4055176A1/fr
Publication of EP4055176A4 publication Critical patent/EP4055176A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP20960974.2A 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination Pending EP4055176A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062932499P 2020-11-07 2020-11-07
US202062933361P 2020-11-08 2020-11-08
PCT/US2020/059752 WO2022098372A1 (fr) 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination

Publications (2)

Publication Number Publication Date
EP4055176A1 EP4055176A1 (fr) 2022-09-14
EP4055176A4 true EP4055176A4 (fr) 2024-04-17

Family

ID=81458164

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20960974.2A Pending EP4055176A4 (fr) 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination

Country Status (3)

Country Link
EP (1) EP4055176A4 (fr)
AU (1) AU2020475819A1 (fr)
WO (1) WO2022098372A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003198A (es) * 2009-10-23 2012-06-12 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022098372A1 *
SNOOK ADAM E. ET AL: "Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 23 April 2019 (2019-04-23), pages 1 - 12, XP055939172, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s40425-019-0576-2/fulltext.html> DOI: 10.1186/s40425-019-0576-2 *
SNOOK ADAM: "Metastatic Colorectal Cancer Immunotherapy with GUCY2C-Expressing Listeria monocytogenes", PROJECT REPORT, 1 September 2018 (2018-09-01), pages 45pp, XP055939177, Retrieved from the Internet <URL:https://apps.dtic.mil/sti/citations/AD1062516> [retrieved on 20220706] *

Also Published As

Publication number Publication date
EP4055176A1 (fr) 2022-09-14
AU2020475819A1 (en) 2022-06-23
WO2022098372A1 (fr) 2022-05-12

Similar Documents

Publication Publication Date Title
EP4114460A4 (fr) Vaccins contre le sras-cov-2 et d&#39;autres coronavirus
EP4112648A4 (fr) Protéine et vaccin contre une infection par sras-cov-2
EP4117725A4 (fr) Méthodes et compositions de vaccin contre le coronavirus
EP3900741A4 (fr) Vaccin à arnsam et procédé de préparation associé
EP3983085A4 (fr) Nouvel adjuvant pour vaccins animaliers et humains
EP3600396A4 (fr) Composition vaccinale d&#39;acide nucléique comprenant une formulation lipidique, et procédé permettant d&#39;augmenter l&#39;efficacité de vaccins d&#39;acide nucléique
EP4154905A4 (fr) Vaccin antitumoral, son procédé de préparation et son utilisation
EP3261667A4 (fr) Composition de vaccin comprenant une protéine immunogène et une combinaison d&#39;adjuvants destinés à être utilisés pour déclencher des réponses de lymphocytes t spécifiques à un antigène
EP4034548A4 (fr) Vaccins à coronavirus et leurs utilisations
EP3127552A4 (fr) Préparation de réseau de micro-aiguilles comprenant un vaccin à virus entier inactivé, et son procédé d&#39;administration
EP4034159A4 (fr) Néoglycoconjugués utilisés en tant que vaccins et outils thérapeutiques
EP4213872A4 (fr) Vaccin à base de piv5 contre la covid-19
EP3730620A4 (fr) Vaccin antigénique à immunisation croisée et son procédé de préparation
EP3897712A4 (fr) Formulations et procédés de vaccin contre les norovirus
EP3856895A4 (fr) Vaccins autologues bihapténisés et leurs utilisations
EP3762022A4 (fr) Vaccins contre le papillomavirus humain et utilisations de ces derniers
EP3703745A4 (fr) Conjugués immunogènes et méthodes d&#39;utilisation de ceux-ci
EP4031169A4 (fr) Vaccins pour abeilles et procédés d&#39;utilisation
EP3838916A4 (fr) Vaccin ayant une utilité dans la prévention contre une infection par toxoplasma gondii et procédé de préparation associé
EP3549604A4 (fr) Vaccin inactivé bivalent recombinant pour la fièvre aphteuse et procédé de préparation et application de celui-ci
EP3959221A4 (fr) Klebsiella vaccin contre la et méthodes d&#39;utilisation
EP4055176A4 (fr) Vaccins anti-gucy2c et vaccination
EP3923981A4 (fr) Adjuvants et formulations de vaccins
EP4240774A4 (fr) Constructions, vaccins et méthodes contre le sars-cov-2
EP3897691A4 (fr) Vaccins contenant de l&#39;il-10 et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240318

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20240312BHEP

Ipc: A61K 35/76 20150101ALI20240312BHEP

Ipc: C12N 5/10 20060101ALI20240312BHEP

Ipc: C12N 15/86 20060101ALI20240312BHEP

Ipc: C12N 7/00 20060101ALI20240312BHEP

Ipc: A61K 48/00 20060101ALI20240312BHEP

Ipc: C12N 15/861 20060101AFI20240312BHEP